Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation

Abstract

The objective of this study was to compare the clinical outcomes of osimertinib as a 2nd-line treatment versus as a ≥3rd-line treatment in advanced and recurrent Epidermal Growth Factor Receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M mutations. A total of 158 patients who received osimertinib as sequential treatment were enrolled for final analysis between September 2014 and March 2023. Among these, 99 patients (62.7%) received osimertinib as 2nd-line treatment, while 59 patients (37.3%) were treated with it as ≥3rd-line therapy. We found no significant difference in progression-free survival or overall survival between the two groups. Our findings suggest that osimertinib is not only effective as a 2nd-line therapy but also as a ≥3rd-line treatment, offering promising clinical benefits for advanced and recurrent EGFR-mutant NSCLC patients with acquired T790M mutations.